HO-3867
CAS No. 1172133-28-6
HO-3867 ( HO 3867;HO3867 )
Catalog No. M10576 CAS No. 1172133-28-6
A synthetic curcuminoid that selectively inhibits STAT3 phosphorylation, transcription, and DNA binding without affecting the expression of other active STATs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 63 | Get Quote |
|
5MG | 87 | Get Quote |
|
10MG | 115 | Get Quote |
|
25MG | 237 | Get Quote |
|
50MG | 380 | Get Quote |
|
100MG | 605 | Get Quote |
|
200MG | 843 | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameHO-3867
-
NoteResearch use only, not for human use.
-
Brief DescriptionA synthetic curcuminoid that selectively inhibits STAT3 phosphorylation, transcription, and DNA binding without affecting the expression of other active STATs.
-
DescriptionA synthetic curcuminoid that selectively inhibits STAT3 phosphorylation, transcription, and DNA binding without affecting the expression of other active STATs; induces G2-M cell cycle arrest in A2780 cells by modulating cell cycle regulatory molecules p53, p21, p27, CDK 2, and cyclin, and promotes apoptosis, inhibits pSTAT3 (Tyr705 and Ser727) and JAK1 and increases apoptotic markers cleaved caspase-3 and PARP in xenograft tumor tissues.
-
SynonymsHO 3867;HO3867
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorSTAT3
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1172133-28-6
-
Formula Weight464.55
-
Molecular FormulaC28H30F2N2O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 32 mg/mL
-
SMILESO=C1/C(CN(CC2=CC(C)(C)N(O)C2(C)C)C/C1=C\C3=CC=C(F)C=C3)=C/C4=CC=C(F)C=C4
-
Chemical Name4-Piperidinone, 1-[(2,5-dihydro-1-hydroxy-2,2,5,5-tetramethyl-1H-pyrrol-3-yl)methyl]-3,5-bis[(4-fluorophenyl)methylene]-, (3E,5E)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Rath KS, et al. Cancer Res. 2014 Apr 15;74(8):2316-27.
2. Selvendiran K, et al. Mol Cancer Ther. 2010 May;9(5):1169-79.
3. Selvendiran K, et al. Cancer Biol Ther. 2011 Nov 1;12(9):837-45.
2. Selvendiran K, et al. Mol Cancer Ther. 2010 May;9(5):1169-79.
3. Selvendiran K, et al. Cancer Biol Ther. 2011 Nov 1;12(9):837-45.
molnova catalog
related products
-
LLL3
LLL3 is a structural analogue of STA-21 that acts as a novel STAT3 inhibitor.
-
HJC0152
A potent, orally bioavailable STAT3 signaling inhibitor that exhibits promising antitumor effects in vitro and in vivo.
-
BP-5-087
A potent, selective STAT3 SH2 domain inhibitor (EC50=5.6 uM) that reduces STAT3 phosphorylation and nuclear transactivation.